Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Says Genomics Revenue Significantly Lower Than Expected for Q2 and 2005

NEW YORK, June 22 (GenomeWeb News) - Gene Logic said today that revenue for its genomics division will be "significantly lower" than anticipated for both the second quarter and the full year of 2006, and it is withdrawing its financial guidance for 2006 and 2007 as a result.

 

The disappointing revenues will adversely impact operating results for the genomics division "for the foreseeable future," the company said.

 

The company said it is performing a review of the genomics division's strategy, and it expects to announce those results within 90 days. The performance of Gene Logic's drug-repositioning division and its preclinical division will not deviate significantly from estimates, the company said.

 

The company's senior vice president and general manager of genomics has resigned for "personal reasons and to pursue other career opportunities," the company said.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.